Gastroenterology
Volume 139, Issue 2 , Pages 393-408.e2 , August 2010

Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment

  • Antonello Pietrangelo

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Antonello Pietrangelo, MD, PhD, 2nd Division of Medicine and Center for Hemochromatosis, University Hospital of Modena, Via del Pozzo 71, 41100 Modena, Italy

Received 1 April 2010 ,Accepted 3 June 2010.

References 

  1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408
  2. London IM. Iron and heme: crucial carriers and catalysts. In:  Wintrobe MM editors. Blood pure and eloquent. New York, NY: McGraw-Hill; 1980;p. 171–208
  3. Laufberger V. Sur la cristallisation de la ferritine. Soc Chim Biol. 1937;19
  4. Widdowson EM, McCance RA. The absorption and excretion of iron before, during and after a period of very high intake. Biochem J. 1937;31:2029–2034
  5. Trousseau A. Glycosurie; diabete sucre. Clinique Med de l'Hotel de Paris. 1865;2:663–698
  6. Guggenheim K. Chlorosis: the rise and disappearance of a nutritional disease. J Nutr. 1995;125:1822–1825
  7. Troisier M. Diabète sucré. Bull Soc Anatomique Paris. 1871;44:231–235
  8. Hanot VC, Chauffard AME. Cirrhose hypertrophique pigmentaire dans le diabète sucré. Revue de Médecine Paris. 1882;2:385–403
  9. Sheldon J. Haemochromatosis. Oxford University Press; 1935;
  10. Alper T, Savage DV, Bothwell TH. Radioiron studies in a case of hemochromatosis. J Lab Clin Med. 1951;37:665–675
  11. Davis WD, Arrowsmith WR. The effect of repeated bleeding in hemochromatosis. J Lab Clin Med. 1950;36:814–815
  12. MacDonald RA. Idiopathic hemochromatosis (A variant of portal cirrhosis and idiopathic hemosiderosis). Arch Intern Med. 1961;107:606–616
  13. Simon M, Pawlotsky Y, Bourel M, et al. Letter: Idiopathic hemochromatosis associated with HL-A 3 tissular antigen [in French]. Nouv Presse Med. 1975;4:1432
  14. Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. [see comments] N Engl J Med. 1999;341:725–732
  15. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001;108:619–623
  16. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906–19912
  17. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403:776–781
  18. McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000;5:299–309
  19. Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2 (A new member of the transferrin receptor-like family). J Biol Chem. 1999;274:20826–20832
  20. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14–15
  21. Plattner HC, Nussbaumer T, Rywlin A. [Juvenile and familial hemochromatosis with endocrinomyocardiac syndrome.]. Helv Med Acta. 1951;18:499–502
  22. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–150
  23. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811–7819
  24. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810
  25. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21–22
  26. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77–82
  27. Von Recklinghausen FD. Uber Haemochromatose. Taggeblatt der (62) Versammlung deutscher Naturforscher and Aerzte in Heidelberg. 1889;324–325
  28. Sham RL, Phatak PD, West C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis. 2005;34:157–161
  29. Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood. 2009;114:20–25
  30. Courselaud B, Pigeon C, Inoue Y, et al. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism (Cross-talk between C/EBP pathway and iron metabolism). J Biol Chem. 2002;277:41163–41170
  31. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2:399–409
  32. Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–487
  33. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–481
  34. Lee DH, Zhou LJ, Zhou Z, et al. Neogenin inhibits HJV secretion and regulates BMP induced hepcidin expression and iron homeostasis. Blood. 2010;115:3136–3145
  35. Smith PM, Godfrey BE, Williams R. Iron absorption in idiopathic haemochromatosis and its measurement using a whole-body counter. Clin Sci. 1969;37:519–531
  36. Bothwell TH, Hurtado AV, Donohue DM, et al. Erythrokinetics (IV. The plasma iron turnover as a measure of erythropoiesis). Blood. 1957;12:409–427
  37. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood. 1989;74:844–851
  38. McLaren GD, Nathanson MH, Jacobs A, et al. Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. J Lab Clin Med. 1991;117:390–401
  39. Lesnefsky EJ, Moghaddas S, Tandler B, et al. Mitochondrial dysfunction in cardiac disease: ischemia–reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001;33:1065–1089
  40. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008;28:197–213
  41. Finch C. Regulators of iron balance in humans. Blood. 1994;84:1697–1702
  42. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780–8785
  43. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99:4596–4601
  44. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093
  45. Nemeth E, Preza GC, Jung CL, et al. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood. 2006;107:328–333
  46. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18:2569–2578
  47. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037–1044
  48. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926–1932
  49. Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood. 2008;111:5727–5733
  50. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101
  51. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114:181–186
  52. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320:1088–1092
  53. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40:569–571
  54. Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8:502–511
  55. Ganz T. Hepcidin--a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol. 2006;306:183–198
  56. Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. Science. 2009;325:877–880
  57. Corradini E, Babitt JL, Lin HY. The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev. 2009;20:389–398
  58. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005;106:2884–2889
  59. Zhang AS, West AP, Wyman AE, et al. Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells. J Biol Chem. 2005;280:33885–33894
  60. Yang F, West AP, Allendorph GP, et al. Neogenin interacts with hemojuvelin through its two membrane-proximal fibronectin type III domains. Biochemistry. 2008;47:4237–4245
  61. Xia Y, Babitt JL, Sidis Y, et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008;111:5195–5204
  62. Zhang AS, Yang F, Meyer K, et al. Neogenin-mediated hemojuvelin shedding occurs after hemojuvelin traffics to the plasma membrane. J Biol Chem. 2008;283:17494–17502
  63. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998;95:1472–1477
  64. Pietrangelo A, Rocchi E, Ferrari A, et al. Regulation of hepatic transferrin, transferrin receptor and ferritin genes in human siderosis. Hepatology. 1991;14:1083–1089
  65. Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med. 2004;350:2383–2397
  66. Ahmad KA, Ahmann JR, Migas MC, et al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis. 2002;29:361–366
  67. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669–673
  68. Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood. 2003;102:371–376
  69. Vujic Spasic M, Kiss J, Herrmann T, et al. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood. 2007;109:4511–4517
  70. Vujic Spasic M, Kiss J, Herrmann T, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab. 2008;7:173–178
  71. Fleming RE, Ahmann JR, Migas MC, et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A. 2002;99:10653–10658
  72. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006;281:28494–28498
  73. Schmidt PJ, Toran PT, Giannetti AM, et al. The transferrin receptor modulates hfe-dependent regulation of hepcidin expression. Cell Metab. 2008;7:205–214
  74. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38:531–539
  75. Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117:1933–1939
  76. Mleczko-Sanecka K, Casanovas G, Ragab A, et al. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood. 2010;115:2657–2665
  77. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112:1503–1509
  78. Corradini E, Garuti C, Montosi G, et al. Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology. 2009;137:1489–1497
  79. Kautz L, Meynard D, Besson-Fournier C, et al. BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood. 2009;114:2515–2520
  80. Huang FW, Pinkus JL, Pinkus GS, et al. A mouse model of juvenile hemochromatosis. J Clin Invest. 2005;115:2187–2191
  81. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest. 2005;115:2180–2186
  82. Kawabata H, Fleming RE, Gui D, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 2005;105:376–381
  83. Viatte L, Lesbordes-Brion JC, Lou DQ, et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood. 2005;105:4861–4864
  84. Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803–1806
  85. Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128:470–479
  86. Wallace DF, Summerville L, Crampton EM, et al. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology. 2009;50:1992–2000
  87. EASL Clinical Practice Guidelines on Hemochromatosis. J Hepatol. 2010;53:3–22
  88. Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275–278
  89. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769–1778
  90. Distante S, Robson KJ, Graham-Campbell J, et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004;115:269–279
  91. Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002;122:646–651
  92. Lim EM, Rossi E, De Boer WB, et al. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int. 2004;24:631–636
  93. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol. 2006;4:1403–1410
  94. Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009;50:94–101
  95. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004;32:131–138
  96. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929–936
  97. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006;145:209–223
  98. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294–301
  99. Gleeson F, Ryan E, Barrett S, et al. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol. 2004;16:859–863
  100. Olynyk JK, Hagan SE, Cullen DJ, et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004;79:309–313
  101. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914–2919
  102. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–230
  103. Jacolot S, Le Gac G, Scotet V, et al. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood. 2004;103:2835–2840
  104. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet. 2004;13:1913–1918
  105. Lee PL, Gelbart T, West C, et al. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol Dis. 2001;27:783–802
  106. Lee P, Gelbart T, West C, et al. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis. 2002;29:471–487
  107. Van Vlierberghe H, Langlois M, Delanghe J, et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol. 2001;35:707–711
  108. Carter K, Bowen DJ, McCune CA, et al. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol. 2003;122:326–332
  109. Kelleher T, Ryan E, Barrett S, et al. DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cells Mol Dis. 2004;33:35–39
  110. Osterreicher CH, Datz C, Stickel F, et al. TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005;31:142–148
  111. Milet J, Dehais V, Bourgain C, et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet. 2007;81:799–807
  112. Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281–289
  113. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002;36:673–678
  114. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627–633
  115. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28:213–214
  116. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256–1262
  117. Kowdley KV, Brandhagen DJ, Gish RG, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129:494–503
  118. Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood. 2010;115:94–96
  119. Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet. 2009;41:1170–1172
  120. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology. 2007;46:1291–1301
  121. Schade AL, Caroline L. An iron-binding component in human blood plasma. Science. 1946;104:340–341
  122. Davis WD, Laurens H. Correlation of results of liver function tests and liver biopsy in hepatic disease. South Med J. 1950;43:217–223
  123. Finch S, Finch C. Idiopathic hemochromatosis, an iron storage disease: A (Iron metabolism in hemochromatosis). Medicine. 1955;34:381–430
  124. Crosby WH. The control of iron balance by the intestinal mucosa. Blood. 1963;22:441–449
  125. Williams R, Smith PM, Spicer EJ, et al. Venesection therapy in idiopathic haemochromatosis (An analysis of 40 treated and 18 untreated patients). Q J Med. 1969;38:1–16
  126. Zahringer J, Konijn AM, Baliga BS, et al. Mechanism of iron induction of ferritin synthesis. Biochem Biophys Res Commun. 1975;65:583–590
  127. Bacon BR, Tavill AS, Brittenham GM, et al. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 1983;71:429–439
  128. Aziz N, Munro HN. Iron regulates ferritin mRNA translation through a segment of its 5' untranslated region. Proc Natl Acad Sci U S A. 1987;84:8478–8482
  129. Hentze MW, Caughman SW, Rouault TA, et al. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science. 1987;238:1570–1573
  130. Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318:1355–1362
  131. Pietrangelo A, Gualdi R, Casalgrandi G, et al. Enhanced hepatic collagen type I mRNA expression into fat-storing cells in a rodent model of hemochromatosis. Hepatology. 1994;19:714–721
  132. Fleming MD, Trenor CC, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997;16:383–386
  133. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997;388:482–488
  134. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343:1529–1535
  135. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211–218
  136. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718–724
  137. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006;281:28494–28498

 Conflicts of interest The author discloses no conflicts.

 Funding Supported by the PRIN 2008 grant from the Italian National Research Council.

PII: S0016-5085(10)00872-3

doi: 10.1053/j.gastro.2010.06.013

Gastroenterology
Volume 139, Issue 2 , Pages 393-408.e2 , August 2010

Article Tools

* Image Usage & Resolution